Chronic Myeloid Leukemia

CHRONIC MYELOID LEUKEMIA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia

The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
Reliability of Laboratory-Developed Tests Called Into Question

A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.

VIDEO SERIES

Ponatinib for CML

Progress in the CML Landscape

Treatment Options

Sequencing Treatment

Choosing the Appropriate TKI

Monitoring Treatment Response

Monitoring Adherence

Switching Therapies

Discontinuing Treatment

Known Factors in TKI Resistance

Managing Adverse Events

Allogeneic Stem Cell Transplant

CML: On the Horizon

The Future of CML Treatment

CHRONIC MYELOID LEUKEMIA NEWS

FDA_drug approval

Iclusig Approved for Resistant or Intolerant Chronic-Phase CML

December 28, 2020

AI-Based Model Made Optimal Selections of Frontline TKI Therapy in CML

December 10, 2020

STAMP Inhibitor May Be a New Treatment Option in CML

December 8, 2020

The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerg

Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

December 8, 2020

Managing adverse effects after starting a TKI can be challenging, and health care practitioners ofte

First-line Therapy Response vs Switching Treatments in Chronic Myeloid Leukemia

October 19, 2020

Next post in Chronic Myeloid Leukemia

AI-Based Model Made Optimal Selections of Frontline TKI Therapy in CML